<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006245</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068176</org_study_id>
    <secondary_id>MSKCC-00060</secondary_id>
    <secondary_id>NCI-1672</secondary_id>
    <nct_id>NCT00006245</nct_id>
  </id_info>
  <brief_title>Flavopiridol and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer That Has Not Responded to Previous Paclitaxel</brief_title>
  <official_title>Phase II Trial of Flavopiridol and Paclitaxel in Patients With Paclitaxel-Refractory Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining flavopiridol and paclitaxel&#xD;
      in treating patients who have locally advanced or metastatic esophageal cancer that has not&#xD;
      responded to previous paclitaxel therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the response rate in patients with paclitaxel-refractory locally advanced or&#xD;
           metastatic esophageal cancer treated with sequential paclitaxel and flavopiridol.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Assess the quality of life of patients treated with this regimen.&#xD;
&#xD;
        -  Obtain pharmacokinetic information about this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive paclitaxel IV over 3 hours on day 1 and flavopiridol IV continuously over 24&#xD;
      hours on day 2 weekly for 3 weeks. Courses repeat every 3 weeks in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Quality of life is assessed at baseline, after courses 1 and 2, and then every 2 courses&#xD;
      thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12-37 patients will be accrued for this study within 6-18&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2000</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Esophageal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alvocidib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed squamous cell carcinoma or adenocarcinoma of the esophagus or&#xD;
             carcinoma of the gastroesophageal (GE) junction&#xD;
&#xD;
               -  If tumor extends below the GE junction into the proximal stomach, 50% of the&#xD;
                  tumor must involve the esophagus or GE junction&#xD;
&#xD;
               -  No gastric cancers with only a minor involvement of the GE junction or distal&#xD;
                  esophagus&#xD;
&#xD;
          -  Metastatic or locally advanced disease that is considered surgically unresectable&#xD;
&#xD;
          -  Must have failed a prior chemotherapy regimen that included paclitaxel for metastatic&#xD;
             disease OR&#xD;
&#xD;
          -  Failed prior combination taxane-based chemotherapy and radiotherapy for locally&#xD;
             advanced disease&#xD;
&#xD;
               -  Must have documented evidence of the following:&#xD;
&#xD;
                    -  Disease progression while on taxane-based neoadjuvant or adjuvant therapy OR&#xD;
&#xD;
                    -  Recurrent disease within 6 months of therapy&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  Accurately measured in at least 1 dimension&#xD;
&#xD;
                    -  At least 20 mm by conventional techniques OR&#xD;
&#xD;
                    -  At least 10 mm by spiral CT scan&#xD;
&#xD;
               -  The following are considered nonmeasurable:&#xD;
&#xD;
                    -  Bone lesions&#xD;
&#xD;
                    -  Leptomeningeal disease&#xD;
&#xD;
                    -  Ascites&#xD;
&#xD;
                    -  Pleural/pericardial effusions&#xD;
&#xD;
                    -  Inflammatory breast disease&#xD;
&#xD;
                    -  Lymphangitis cutis/pulmonis&#xD;
&#xD;
                    -  Abdominal masses that are not confirmed and followed by imaging techniques&#xD;
&#xD;
                    -  Cystic lesions&#xD;
&#xD;
          -  No brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute granulocyte count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 150,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No active angina or myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No significant ventricular arrhythmia requiring antiarrhythmic medication&#xD;
&#xD;
          -  Atrial fibrillation that is well controlled on standard management allowed&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 2 months after study&#xD;
&#xD;
          -  No preexisting peripheral neuropathy of grade 2 or greater&#xD;
&#xD;
          -  No serious concurrent infection&#xD;
&#xD;
          -  No uncontrolled, nonmalignant medical illness that would preclude study&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No other active malignancy within the past 5 years except:&#xD;
&#xD;
          -  Nonmelanoma skin cancer or&#xD;
&#xD;
          -  Carcinoma in situ of the cervix&#xD;
&#xD;
          -  History of T1a or T1b prostate cancer (detected incidentally during transurethral&#xD;
             resection of the prostate and comprising less than 5% of resected tissue) allowed if&#xD;
             PSA normal since surgery&#xD;
&#xD;
          -  No medical or psychiatric condition that would preclude study compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No more than 6 months since prior paclitaxel&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior radiotherapy allowed (indicator lesion must be outside of prior radiation port&#xD;
             unless recent evidence of disease progression at that site)&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No prior cyclin-dependent kinase or protein kinase C inhibitors for esophageal cancer&#xD;
&#xD;
          -  Recovered from toxic effects of any prior therapy&#xD;
&#xD;
          -  No concurrent vitamins, antioxidants or herbal preparations or supplements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary K. Schwartz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Rathkopf DE, Ilson DH, Yi S, et al.: A phase II trial of sequential paclitaxel and flavopiridol in patients with metastatic paclitaxel-refractory esophageal cancer. [Abstract] American Society of Clinical Oncology 2004 Gastrointestinal Cancers Symposium, 22-24 January 2004, San Francisco, CA. A-67, 2004.</citation>
  </results_reference>
  <verification_date>April 2004</verification_date>
  <study_first_submitted>September 11, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 20, 2013</last_update_submitted>
  <last_update_submitted_qc>June 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2013</last_update_posted>
  <keyword>stage III esophageal cancer</keyword>
  <keyword>stage IV esophageal cancer</keyword>
  <keyword>recurrent esophageal cancer</keyword>
  <keyword>squamous cell carcinoma of the esophagus</keyword>
  <keyword>adenocarcinoma of the esophagus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Alvocidib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

